Xiidra vs Tepezza
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Tepezza | |
|---|---|---|
| Generic name | lifitegrast | teprotumumab |
| Drug class | LFA-1 Antagonist (Eye Drop) | IGF-1R Inhibitor (Biologic) |
| Treats | Dry eye disease | Thyroid eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | Amgen |
| Year approved | 2016 | 2020 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $150M | — |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Muscle spasms, Nausea, Hair loss, Hearing problems |
Frequently asked questions
Is Xiidra or Tepezza better?
Neither is universally "better." Xiidra (lifitegrast) and Tepezza (teprotumumab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Tepezza?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.